Apport du bleu de toluidine en cancérologie bucco-pharyngo-oesophagienne [Contribution of Toluidine blue to bucco-pharyngo-oesophageal cancerology]

En muqueuse malpighienne lisse, le Bleu de Toluidine présente un intérêt diagnostic considérable, non seulement lors de l'endoscopie, mais lors de la chirurgie d'exérèse des carcinomes intra-épithéliaux et micro-invasifs de la voie digestive supérieure (bouche, pharynx, oesophage). L'utilisation systématique de ce colorant vital nous a permis le diagnostic et l'étude morphologique endoscopique de 18 carcinomes « précoces » de l'oesophage (9 in situ, 3 dysplasies sévères, 1 microinvasif, 5 limités à la sous-muqueuse). La multicentricité et la multifocalité de ces lésions est fréquente (80 à 90 % des cas), ce qui impose leur exérèse chirurgicale sous Bleu de Toluidine, afin de détecter les foyers de carcinome in situ à distance de la lésion primaire. La connaissance exacte des faux positifs et négatifs permet de limiter les erreurs d'interprétation lors de la coloration.

Apport des technologies mobiles à l'amélioration des soins en cancérologie

Réalisé en cotutelle avec Claude Sicotte PhD Université de Montréal et le Pr. Étienne Minvielle École des Hautes Études en Santé Publique à Paris.

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

BACKGROUND: Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended for patients older than 70 years. We compared a carboplatin and paclitaxel doublet chemotherapy regimen with monotherapy in elderly patients with advanced NSCLC. METHODS: In this multicentre, open-label, phase 3, randomised trial we recruited patients aged 70-89 years with locally advanced or metastatic NSCLC and WHO performance status scores of 0-2. Patients received either four cycles (3 weeks on treatment, 1 week off treatment) of carboplatin (on day 1) plus paclitaxel (on days 1, 8, and 15) or five cycles (2 weeks on treatment, 1 week off treatment) of vinorelbine or gemcitabine monotherapy. Randomisation was done centrally with the minimisation method. The primary endpoint was overall survival, and analysis was done by intention to treat. This trial is registered, number NCT00298415. FINDINGS: 451 patients were enrolled. 226 were randomly assigned monotherapy and 225 doublet chemotherapy. Median age was 77 years and median follow-up was 30.3 months (range 8.6-45.2). Median overall survival was 10.3 months for doublet chemotherapy and 6.2 months for monotherapy (hazard ratio 0.64, 95% CI 0.52-0.78; p<0.0001); 1-year survival was 44.5% (95% CI 37.9-50.9) and 25.4% (19.9-31.3), respectively. Toxic effects were more frequent in the doublet chemotherapy group than in the monotherapy group (most frequent, decreased neutrophil count (108 [48.4%] vs 28 [12.4%]; asthenia 23 [10.3%] vs 13 [5.8%]). INTERPRETATION: Despite increased toxic effects, platinum-based doublet chemotherapy was associated with survival benefits compared with vinorelbine or gemcitabine monotherapy in elderly patients with NSCLC. We feel that the current treatment paradigm for these patients should be reconsidered. FUNDING: Intergroupe Francophone de Cancérologie Thoracique, Institut National du Cancer.

Probe-level linear model fitting and mixture modeling results in high accuracy detection of differential gene expression

Affiliation: Institut de recherche en immunologie et en cancérologie, Université de Montréal

Prevalencia de ideación suicida y factores de riesgo para el suicidio en pacientes adultos con diagnóstico de cáncer.

determinar la prevalencia de ideación suicida y factores asociados en una muestra voluntaria de 114 pacientes oncológicos adultos. Método: Se entrevistaron los pacientes y se evaluó la presencia de ideación suicida (Escala de ideación suicida), depresión (Inventario de Depresión de Beck) y desesperanza (Escala de desesperanza de Beck). Resultados: La prevalencia de ideación suicida fue de 23,7%, se observaron altos niveles de depresión y desesperanza; así como asociación estadísticamente significativa entre ideación suicida y depresión. Conclusión: Se identificó la importancia de la intervención psicológica en los pacientes oncológicos.

Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?

SCOPUS: ed.j

Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies

Background: The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature ovarian failure (POF) is still controversial. Our meta-analysis of randomized, controlled trials (RCTs) investigates whether the use of LHRHa during chemotherapy in premenopausal breast cancer patients reduces treatment-related POF rate, increases pregnancy rate, and impacts disease-free survival (DFS). Methods: A literature search using PubMed, Embase, and the Cochrane Library, and the proceedings of major conferences, was conducted up to 30 April 2015. Odds ratios (ORs) and 95% confidence intervals (CIs) for POF (i.e. POF by study definition, and POF defined as amenorrhea 1 year after chemotherapy completion) and for patients with pregnancy, as well hazard ratios (HRs) and 95% CI for DFS, were calculated for each trial. Pooled analysis was carried out using the fixed- and random-effects models. Results: A total of 12 RCTs were eligible including 1231 breast cancer patients. The use of LHRHa was associated with a significant reduced risk of POF (OR 0.36, 95% CI 0.23-0.57; P < 0.001), yet with significant heterogeneity (I2 = 47.1%, Pheterogeneity = 0.026). In eight studies reporting amenorrhea rates 1 year after chemotherapy completion, the addition of LHRHa reduced the risk of POF (OR 0.55, 95% CI 0.41-0.73, P < 0.001) without heterogeneity (I2 = 0.0%, Pheterogeneity = 0.936). In five studies reporting pregnancies, more patients treated with LHRHa achieved pregnancy (33 versus 19 women; OR 1.83, 95% CI 1.02-3.28, P = 0.041; I2 = 0.0%, Pheterogeneity = 0.629). In three studies reporting DFS, no difference was observed (HR 1.00, 95% CI 0.49-2.04, P = 0.939; I2 = 68.0%, Pheterogeneity = 0.044). Conclusion: Temporary ovarian suppression with LHRHa in young breast cancer patients is associated with a reduced risk of chemotherapy-induced POF and seems to increase the pregnancy rate, without an apparent negative consequence on prognosis.

Paraneoplastic syndromes

Abstract: There are two types of clinical and biochemical syndromes not directly associated with the invasiveness and metastatic ability of the tumour; the first type is represented by the hormonal paraneoplastic syndromes. The second type consists of certain neurological diseases or abnormalities observed in patients with malignant tumours not directly affecting the nervous system. While the hormonal type is well established and rests on solid ground, the neurological type is less well defined and more controversial. © 1981 Pergamon Press Ltd.

Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies

International audience

Editorial Introductions

SCOPUS: ed.j